1. Home
  2. NBIX vs IESC Comparison

NBIX vs IESC Comparison

Compare NBIX & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$166.05

Market Cap

15.5B

Sector

Health Care

ML Signal

HOLD

Logo IES Holdings Inc.

IESC

IES Holdings Inc.

BUY

Current Price

$169.07

Market Cap

12.7B

Sector

Industrials

ML Signal

BUY

Company Overview

Basic Information
Metric
NBIX
IESC
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Engineering & Construction
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
15.5B
12.7B
IPO Year
1996
1997

Fundamental Metrics

Financial Performance
Metric
NBIX
IESC
Price
$166.05
$169.07
Analyst Decision
Strong Buy
Analyst Count
29
0
Target Price
★ $207.50
N/A
AVG Volume (30 Days)
★ 1.3M
421.1K
Earning Date
11-02-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
41.95
★ 51.87
EPS
5.26
★ 17.52
Revenue
$161,626,000.00
★ $3,371,468,000.00
Revenue This Year
$36.46
$25.64
Revenue Next Year
$17.43
$48.14
P/E Ratio
$31.49
★ $11.53
Revenue Growth
★ 977.51
16.89
52 Week Low
$122.14
$194.32
52 Week High
$186.12
$816.51

Technical Indicators

Market Signals
Indicator
NBIX
IESC
Relative Strength Index (RSI) 76.47 24.94
Support Level $152.67 N/A
Resistance Level $169.57 $349.66
Average True Range (ATR) 3.61 13.78
MACD 2.23 0.59
Stochastic Oscillator 86.44 12.74

Price Performance

Historical Comparison
NBIX
IESC

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About IESC IES Holdings Inc.

IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.

Share on Social Networks: